Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Impact · against what's priced in

The simultaneous launch of ORZEYFUL in Japan and China provides Takeda with a first-in-class revenue stream for Narcolepsy Type 1. This establishes immediate commercial presence in two key markets with a high-margin, novel mechanism of action.

4502+0.60: No priced-in read yet

Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

What matters in this story

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

What matters in this story

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

How each ticker is affected

Track these names every morning.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

What matters in this story

Next reads from the same story arc

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

What matters in this story

Next reads from the same story arc

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

How each ticker is affected

Track these names every morning.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit